Project Grant R01MH132965
- BRAIN-START Cooperative Agreement Summary The National Institute on Aging (Aging Research, CFDA 93.866) awarded a $899,582 Cooperative Agreement to the Aga Khan University-Kenya on September 23, 2025, with completion targeted for August 31, 2030. The Aga Khan University-Kenya will develop and deliver scalable diagnostic technologies for Alzheimer's Disease and Related Dementias (ADRD) assessment in low- and middle-income countries, addressing the critical gap that approximately 60% of global...
- This $174,788 National Science Foundation (NSF) award under the Computer and Information Science and Engineering (CISE) program focuses on enhancing the assessment and diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The project aims to develop computational approaches to collect and analyze ADHD-related data, leveraging technologies such as inertial movement units, touch-sensitive screens, and high-precision cameras to gather insights into hyperactivity behaviors. The goal is to...
- Cincinnati Children's Hospital Medical Center was awarded $820,196 by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) on March 5, 2026, for a five-year project extending through February 28, 2031. This Project Grant funds observational and mechanistic research investigating the impact of circadian misalignment on adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). The research addresses a critical gap in understanding how...
- Cooperative Agreement Summary New York University School of Medicine received a $7.68 million Cooperative Agreement from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) awarded September 1, 2025, with completion targeted for August 31, 2029. The Behavioral Phenoscreening: Remote Assessment of Child Mental Health (REACH) project will develop and validate computer vision and machine learning-based approaches to enable early...
- Federal Cooperative Agreement Summary The National Institute of Mental Health awarded a $7.01 million Cooperative Agreement under the Mental Health Research Grants program (CFDA 93.242) to Massachusetts General Hospital for the SPARC-XP (Scalable Phenotyping to Assay Risk in Childhood After Exposures in Pregnancy) project. This four-year initiative (September 1, 2025 – August 31, 2029) will develop and validate predictive risk models to identify which offspring of mothers with infections...
- Federal Project Grant Award Summary Kennesaw State University received a $540K Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective September 1, 2025, through August 31, 2028. The award funds basic neuroscience research investigating the role of the homeobox transcription factor NKX2.1 in nervous system development, with particular emphasis...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital a $1.73 million Project Grant on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate cognitive impairment, Alzheimer's disease and related dementias (ADRD), and mild cognitive impairment (MCI) among people living with HIV (PWH) in Uganda. The research addresses a significant public health gap by establishing prevalence and disease trajectories of cognitive...
- Federal Project Grant Award Summary The Institute of Education Sciences (IES) awarded Children's Research Institute a $448,057 Project Grant on October 1, 2025, under the Research in Special Education program (CFDA 84.324) to conduct a longitudinal evaluation of promotive and protective factors for academic functioning among students with Attention-Deficit/Hyperactivity Disorder (ADHD) across the transition to middle school. The research project, which extends through June 30, 2026, will be...
- The National Institute of Mental Health (NIMH) awarded a $990,550 Project Grant to Boston Children's Hospital under the Mental Health Research Grants program (CFDA 93.242) on March 10, 2026, to develop and test a novel cognitive control and metacognition training intervention for school-aged children with autism spectrum disorder (ASD). The research will deliver computer-based cognitive control training combined with metacognition coaching, administered individually by a trained coach to...
- Federal Grant Award Summary The National Institute of Child Health and Human Development (NICHD) awarded $765,377 to The Children's Hospital of Philadelphia Research Institute through the Child Health and Human Development Extramural Research program (CFDA 93.865) on June 17, 2026, for a project addressing clinical trial readiness of magnetoencephalography (MEG) biomarkers in children with autism spectrum disorder (ASD). The project will develop standardized, scalable methods to establish the...
2/3 AKILI: PHENOTYPIC AND GENETIC CHARACTERIZATION OF ADHD IN KENYA AND SOUTH AFRICA - PROJECT SUMMARY ADHD IS A COMMON NEURODEVELOPMENTAL DISORDER THAT INCLUDES ATTENTION DIFFICULTY, IMPULSIVITY, AND HYPERACTIVITY. THE DIAGNOSIS IS ASSOCIATED WITH MANY CHALLENGES TO EDUCATIONAL, OCCUPATIONAL, AND HEALTH OUTCOMES, PARTICULARLY WHEN UNTREATED. GENETIC STUDIES OF ADHD HAVE THE POTENTIAL TO CLARIFY THE DISORDER'S BIOLOGICAL UNDERPINNINGS, ITS HETEROGENEITY, AND ITS RELATIONSHIP TO OTHER NEUROPSYCHIATRIC DIAGNOSES. HOWEVER, GENETIC RESEARCH INTO ADHD LAGS IN TERMS OF: (1) SAMPLE SIZE, (2) ANCESTRAL DIVERSITY, AND (3) CONSIDERATION OF PHENOTYPIC HETEROGENEITY. AKILI IS DESIGNED TO ADDRESS ALL THREE OF THESE CRITICAL GAPS. AKILI (THE SWAHILI TERM FOR "MIND") WILL ENROLL 6,000 CHILDREN IN KENYA AND SOUTH AFRICA - 4,000 WITH A CONFIRMED DIAGNOSIS OF ADHD AND 2,000 AGE- AND ANCESTRY-MATCHED CONTROLS. ALL PARTICIPANTS WILL COMPLETE A DETAILED BEHAVIORAL, COGNITIVE, AND MEDICAL PHENOTYPING BATTERY, AND PROVIDE A DNA SAMPLE. WE WILL GENETICALLY CHARACTERIZE ALL 6,000 PARTICIPANTS USING EXOME SEQUENCING AND GENOME-WIDE GENOTYPING, AND MAKE ALL AKILI DATA AND MATERIALS PUBLICLY AVAILABLE THROUGH THE NIMH. AKILI DATA WILL NEARLY DOUBLE THE NUMBER OF ADHD CASES AVAILABLE FOR EXOME SEQUENCING ANALYSIS AND PROVIDE A 20% ADDITION TO THE CURRENT PGC-ADHD GWAS ACTIVITY. IT WILL BE BY FAR THE LARGEST CONTRIBUTOR OF DIVERSE ANCESTRY DATA TO EITHER ANALYSIS. AKILI WILL GENERATE A RESEARCH RESOURCE OF INTERNATIONAL VALUE, AND PROVIDE THE FIRST LARGE-SCALE CHARACTERIZATION OF ADHD IN THE AFRICAN CONTEXT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $498.9k | 6/30/26 | ||
| Not listed | $514.8k | 7/11/25 | ||
| Not listed | $529.7k | 6/12/24 | ||
| Not listed | $0 | 9/4/23 | ||
| Not listed | $0 | 9/4/23 |